Careful examination of viral dynamics during antiretroviral treatment can provide important insights into HIV pathogenesis. We examined viral evolution during and after enfuvirtide (T-20) treatment with an objective of defining the characteristics of viral evolution during advanced HIV immunodeficiency. Specifically, we examined the viral quasispecies from nine patients who experienced incomplete viral suppression on an enfuvirtide-based regimen, and who subsequently interrupted enfuvirtide while remaining on a stable optimized background regimen (enfuvirtide "partial treatment interruption"). On average, eight clones were sequenced from three time points: pre-enfuvirtide, post-enfuvirtide failure, and post-enfuvirtide interruption. We utilized a Bayesian hierarchical phylogenetic model to assess the evolutionary relatedness of the virus that emerged over time. In most subjects, interruption of enfuvirtide was associated with continued viral evolution as enfuvirtide mutations waned; in no subject did we find clear evidence supporting the reemergence of archived wild-type variants (Bayes factor ‫؍‬ 30.2, p ‫؍‬ 0.01). Evidence supporting ongoing viral evolution was particularly strong in subjects whose virus remained diverse or became more diverse during enfuvirtide therapy. In contrast to observations when all drugs are interrupted, loss of resistance during enfuvirtide interruption is most likely due to ongoing viral evolution (and back-mutation), rather than emergence of an archived virus.
INTRODUCTION T
HE POTENTIAL FOR GENETIC VARIATION in HIV-1 is remarkable. Even within a single host, HIV-1 exists as a population of related but genetically distinct variants referred to as a quasispecies. This diversity is a consequence of point mutations, insertions and deletions, and recombination. 1 Although many of these variants are replication defective, variants that have higher relative fitness can persist and emerge as the dominant quasispecies under the selective pressure of antiretroviral therapy and/or host immune responses. This variation poses a formidable obstacle in the successful antiretroviral treatment of HIV-1-infected patients.
Failure to completely suppress viral replication with combination therapy leads to the accumulation of drug-resistance mutations. Although high-level resistance to drugs is commonly observed, plasma HIV-1 RNA levels often remain partially suppressed for prolonged periods of time. This persistent antiviral benefit is due to the residual activity of the therapeutic regimen against the resistant virus as well as the selection of mutations that reduce the capacity of HIV to replicate efficiently (replicative capacity). 2, 3 Enfuvirtide is a 36-amino acid peptide that binds to the HR-1 region of gp41 and prevents fusion of the viral membrane with the target cell membrane. As enfuvirtide is expensive and must be administered parentally, the drug is typically reserved for heavily pretreated patients with limited therapeutic options. When such patients experience virologic failure on an enfuvirtide-containing regimen, they are faced with the decision of whether to continue or to stop the drug (rather than switching to a completely new regimen). To define the degree of residual antiviral activity in patients with enfuvirtide resistance, our group performed a prospective study in which enfuvirtide was interrupted (while all other drugs were continued). Plasma HIV-1 RNA levels increased immediately after enfuvirtide interruption (median change of ϩ0.16 log copies), indicating that the drug retained low-level residual activity against the resistant variant. After a delay of approximately 8 weeks, enfuvirtide genotypic resistance began to wane, and eventually became undetectable in most subjects. This latter observation indicates that enfuvirtide resistance mutations reduce viral fitness (as demonstrated by rapid loss of enfuvirtide mutations in the absence of drug pressure).
The mechanism whereby resistance wanes in the absence of drug remains undefined. Theoretically, an archived enfuvirtidesusceptible "wild-type" virus could emerge from a reservoir. Alternatively, the virus could continue to evolve and "back-mutate" resistance-associated mutations. To define the mechanism for viral evolution in the absence of enfuvirtide, we performed a detailed phylogenetic analysis on longitudinally collected samples from nine subjects who initiated, failed, and subsequently discontinued enfuvirtide therapy. Plasma samples were obtained before initiation of enfuvirtide, the week prior to enfuvirtide interruption, and approximately 16 weeks after the interruption. At each time point a 650-bp fragment of the env gene that included the HR-1 and HR-2 coding region was amplified by nested reverse transcriptase polymerase chain reaction (RT-PCR), cloned, and sequenced. We utilized a Bayesian hierarchical phylogenetic model to assess the evolutionary relatedness of the viral strains within each individual and to assess intrahost evolution across all patients simultaneously. Overall we found strong evidence for ongoing viral evolution in the absence of enfuvirtide pressure rather than for the emergence of an archived wild-type variant. Of note, those subjects who had the greatest increase in diversity during enfuvirtide treatment had the highest support for ongoing viral evolution during the interruption period. Collectively, these data provide indirect evidence suggesting that HIV-1 gp41 continues to evolve and that contemporaneous viruses are more fit than recently archived viruses.
MATERIALS AND METHODS

Study population
Patients were selected from a prospective single arm study of HIV-1-infected patients who had evidence of viral replication while on a stable antiretroviral regimen that included enfuvirtide. All patients interrupted enfuvirtide and remained on a stable background regimen. For this analysis, we selected those subjects for whom we had genotypic sequence data available from three time points: (1) prior to the initiation of enfuvirtide ("pre-enfuvirtide"), (2) after failure of enfuvirtide and just prior to interruption on enfuvirtide ("enfuvirtide failure"), and (3) 16 weeks after interruption of enfuvirtide ("post-enfuvirtide"). All subjects provided informed consent for participation in these studies.
PCR amplification, cloning, and sequencing
Details regarding the clonal analysis are presented elsewhere. 4 Briefly, viral RNA was extracted from plasma using the QIAamp viral RNA kit (Qiagen, Valencia, CA). A 650-bp fragment of the gp41-coding region of env that includes HR-1 and HR-2 regions was amplified by nested RT-PCR. Bidirectional DNA sequencing of the purified PCR products was performed using Applied Biosystems Taq DyeDeoxy Terminator cycle sequencing kits (Applied Biosystems, Foster City, CA).
Recombination detection
All sequences were tested exhaustively for evidence of recombination using a Bayesian dual multiple change-point model 5 as well as RIP 2.0 (Los Alamos database online tools).
Phylogenetic analysis
Sequences were aligned using Clustal W and manually checked. Sequence translations were performed using Mega 3.1. 6 We used a Bayesian hierarchical phylogenetic model with a gamma-distributed rate variation parameter across sites to address questions of intrahost evolution across many patients. In this way we can make probability statements about hypotheses across all patients simultaneously while allowing each individual subject to have different evolutionary parameters. This model uses the Tamura-Nei 7 infinitesimal rate matrix for nucleotide substitution and site-to-site rate variation follows a discrete gamma distribution with four bins. Details of this model are described elsewhere. 8, 9 Models were fitted using Markov chain Monte Carlo (MCMC) with chain lengths of 310,000 iterations. We discarded the first 10,000 observations as burn-in and subsampled every thirtieth observation to yield 10,000 posterior samples with decreased autocorrelation. The models ran in approximately 4 h on a 1-GHz Pentium M PC. Examination of model log-likelihood time series plots showed that the burnin times and the total MCMC chain lengths were significantly longer than what appeared to be required. 10 
Diversity analysis
For each subject, average pairwise diversity at each time point was calculated using the method of Nei and Jin 11 with multiple hits corrected for using the Tamura-Nei model of nucleotide substitution. 7 Standard errors were estimated using 1000 bootstrap replicates. These calculations were performed using the SENDBS program (N. Takezaki, National Institute of Genetics).
Nucleotide sequence accession number
The sequences of the cloned gp41 have been deposited in GenBank under the accession numbers DQ852666-DQ852692.
RESULTS
Subject characteristics
Nine subjects met our inclusion criteria ( Table 1 ). The median pre-enfuvirtide interruption CD4 ϩ T cell count and plasma HIV-1 RNA levels were 12 cells/mm 3 (range: 4-140) and 5.03 log 10 copies/ml (range: 4.45-5.70), respectively. After a median of 28 weeks on enfuvirtide, median CD4 ϩ T cell counts increased to 57 cells/mm 3 (range: . At week 2 of the HIV-1 gp41 EVOLUTION DURING ENFUVIRTIDEenfuvirtide interruption, the median change in viral load from the preinterruption baseline was 0.16 log 10 copies RNA/ml (range: Ϫ0.05, 0.32) and the median change in CD4 T cell count was Ϫ2 cells/mm 3 (range: Ϫ8, 12). By week 16, the median change in log 10 viral load was 0.25 log 10 copies RNA/ml (range: Ϫ0.42, 1.02) and the median change in CD4 T cell counts was Ϫ13 cells/mm 3 (range: Ϫ34, 16). Virus from all subjects had genotypic evidence of enfuvirtide resistance at the time enfuvirtide was interrupted. The proportion of clones containing enfuvirtide resistance mutations in each subject declined in the absence of drug and became undetectable for many patients by week 16 (Table 1) .
Clonal analysis
An average of eight clones (range: 6-14) per time point was available. All sequences were tested for recombination. There was no evidence of recombination within the gp41 sequences (although we were not able to test for recombination between gp41 and the rest of the viral genome). Maximum likelihood trees showed that for each subject, the sequences clustered tightly by time. For each time point, clones were selected for each subject randomly and included in the analysis. To ensure that our results would not be affected by sampling bias, we drew another random sample of clones for each subject time point and repeated the analysis.
The gp41 region of the env gene was analyzed by aligning the serial sequences from each subject. Because of possible bias due to convergent evolution, enfuvirtide resistance-associated mutations in HR-1 were deleted from the alignment. Each alignment contained four sequences: one from before enfuvirtide initiation (pre-enfuvirtide), one during enfuvirtide therapy just before the interruption (enfuvirtide), one approximately 16 weeks after the interruption (post-enfuvirtide), and the outgroup sequence HXB2. There are three possible phylogenetic trees that can be constructed from a dataset containing four sequences. Thus for each person there are three distinct hypotheses that are possible. When the post-enfuvirtide strain is more closely related to the enfuvirtide strain, the hypothesis of continued evolution in gp41 is favored (Fig. 1, Tree E) . If the post-enfuvirtide strain is more closely related to the pre-enfuvirtide strain, then the hypothesis of the reemergence of an archived strain is more likely (Fig. 1, Tree R) . The third tree has post-enfuvirtide and the outgroup as neighbors (Fig. 1, Tree O) and is less likely a priori as our outgroup is HXB2. We placed priors on the probability of each tree such that Trees E and R were equally likely but substantially more likely than Tree O. Thus we set the prior probability of Trees E, R, and O to 0.45, 0.45, and 0.10 respectively. Previously we found that the Bayesian hierarchical phylogenetic model had a better fit than concatenating the sequences of all the patients or analyzing each subject separately, KITCHEN ET AL. 1262 a All distances were estimated using the method of Nei and Jin using the Tamura-Nei ϩ gamma nucleotide substitution model. Standard errors (in parentheses) were estimated using 1000 bootstrap replications.
while allowing us to make overall probability statements of our hypotheses. 8 As described in detail elsewhere, 4 interruption of enfuvirtide was associated with rapid loss of gp41-associated resistance mutations. When all nine subjects were considered in a single model, this loss of resistance reflected continued viral evolution of gp41 in the dominant quasispecies at the time of the interruption rather than reemergence of an archived virus. The posterior mean probability supporting ongoing viral evolution (Tree E) was 0.97 and the posterior mean probability supporting reemergence (Tree R) was 0.03. The Bayesian hierarchical phylogenetic model allows us to estimate the overall probability of competing hypotheses across all patients by the use of Bayes factors. Bayes factors can be thought of as the level of support of one hypothesis over another; in this case, the continued evolution hypothesis versus the reemergence hypothesis. The support in favor of Tree E over Tree R was 30.2, roughly equivalent to a p value of 0.01. 12 When examining the subjects individually using the Bayesian model, we found that four subjects had very strong support for the evolution hypothesis (greater than 99% posterior support for Tree E), two subjects had strong support (greater than 90% posterior probability for Tree E), and three subjects had weak support for the evolution hypothesis (less than 90%) ( Table 2 ). Figure 2 shows the phylogenetic trees from four representative patients. Estimates of the evolutionary parameters showed considerable variability between patients, further demonstrating the need for a hierarchical model. For example, subject 3507 demonstrated the highest rate of evolution while subject 3508 demonstrated the lowest (Table 2 ). There was no statistically significant association with tree support and CD4 ϩ T cell count, log viral load, CD8 ϩ T cell count, or self-reported adherence.
We then estimated the level of within subject diversity at each time point (Table 1) . We found that subjects who had the greatest increase in diversity during enfuvirtide treatment had the highest support for ongoing viral evolution during interruption period (Ͼ99% posterior probability for Tree E; N ϭ 3). Subjects with no change in diversity during enfuvirtide therapy also had strong support for the evolution tree (Ͼ90% posterior probability, N ϭ 3). In contrast, subjects who had a decrease in diversity during enfuvirtide therapy had mixed support or weak support (Ͻ90%) for Tree E.
Subject 3514 was an outlier. There were no clones available at week 16 for this subject and thus we had to use virus isolated at week 25 for the analysis. Week 16 was available for all other subjects. This subject also had the worst self-reported adherence, missing over 50% overall of the enfuvirtide doses. Subject 3514 also reported missing many doses of the background antiretrovirals during enfuvirtide treatment interruption. These factors may explain the difference in the results with this subject versus the other subjects.
We used scaled regeneration quantile (SRQ) plots to assess the performance of our sampler in estimating the posterior probability of a specific tree. Regeneration times are defined as the time it takes a Markov chain once it left a specific tree to return. The ratio of the estimated posterior probability based on the entire chain and the estimated posterior probability based on the chain between tours is the slope between two scaled regeneration times in an SRQ plot. If the slope of the two scaled are the transition/transversion rate ratio of purines and pyrimidines, respectively, ␣ is the gamma shape parameter, is the expected divergence, and is the nucleotide frequencies. regeneration times is substantially different from one, this indicates that the chain is not long enough. Figure 3 shows a representative SRQ plot that shows that our chains are mixing well and are long enough to produce stable posterior estimates.
DISCUSSION
We examined nine subjects with advanced HIV disease who experienced virologic failure on an enfuvirtide-based regimen and who subsequently interrupted this drug while remaining on a stable background regimen. Enfuvirtide resistance mutations in each subject waned rapidly. In contrast to observations when all drugs are interrupted, [13] [14] [15] loss of resistance during enfuvirtide interruption in these subjects occurs due to ongoing viral evolution (and back-mutation), rather than emergence of an archived virus. This was particularly true in patients whose virus remained diverse or became more diverse during enfuvirtide therapy.
The analysis was based upon sampling from an average of eight clones per subject per time point. It is possible that the cloning process selected for minor variants that are not representative of the plasma population. To help ensure against sampling bias, we selected several other clones at random and reran the analysis. The results based on this new sample did not change (data not shown). To help ensure against results biased by phenotypic attraction or convergent evolution, drug resistance-associated sites were deleted from the sequences before the analysis was conducted. Interestingly, the four patients with the highest support for ongoing viral evolution (Tree E) did not have 100% of their clones return to drug-sensitive wild-type by week 16 (range 38-88%). Since these sites KITCHEN ET AL. 1264 
FIG. 2.
Phylogenetic trees from four representative subjects. For each subject, the most probable phylogenetic tree was drawn. A scale bar is drawn for each tree and represents the expected number of nucleotide substitutions per site.
FIG. 3.
SRQ plot to show model mixing and stability of posterior estimates. No significant deviation from a slope of one indicates that our model mixed well and that the chain was long enough to produce stable estimates.
were deleted from the analyses, the conclusions were not biased by this observation. The fact that the virus exhibited ongoing viral evolution in the absence of enfuvirtide was not expected and suggests indirectly that there exist selective pressures on envelope function even in advanced disease. Enfuvirtide is the only approved antiretroviral therapy that inhibits envelop-mediated cell entry. The env gene is a highly immunogenic region of the virus and exhibits high levels of genetic diversity (both within a population and within an individual). The genetic diversity of env initially decreases after infection and then rapidly increases over a period of several years, reaching a maximum as CD4 ϩ T cell counts decrease to below 200 cell/mm 3 . 16, 17 Thereafter, env diversity tends to decrease significantly, as the presumed loss of immunologic control leads to emergence of a dominant, highly fit variant. 17 These observations are supported by recent data indicating that while neutralizing antibody responses exert strong pressures during early HIV infection, they exhibit only limited responses during chronic late-state infection. [18] [19] [20] Since all subjects in this study had a low CD4 ϩ T cell count at the time enfuvirtide was interrupted (median: 57 cells/mm 3 ; range: , limited ongoing immunologic pressure exerted against env might be expected. Although we did not test these issues directly, our observation that the dominant plasma virus present at the time of enfuvirtide interruption persisted and exhibited back-mutation suggests that this virus was relatively more fit than presumed archived drug-susceptible variants. In other words, this enhanced fitness of the drug-resistant over the archived drug-susceptible virus present at the time of the interruption may reflect continued evolution within env in response to unmeasured host responses.
It is also possible that the optimized "background" antiretroviral drugs that were coadministered with enfuvirtide may have selected for a variant that was more resistant to these drugs than the presumably archived pre-enfuvirtide virus population. In this scenario, the continued use of these background drugs acts to prevent the reemergence of the enfuvirtide wildtype variant. However, HIV-1 has an estimated average recombination event of 1 per 1000 base pairs. 21 Although the optimized background antiretrovirals may have created selective pressure preventing emergence of archived protease/reverse transcriptase genes, this mechanism does not explain why the post-enfuvirtide interruption circulating strains did not recombine with the earlier gp41 sequences that are enfuvirtide susceptible.
Understanding the interplay of viral dynamics with host responses is critical to our understanding of HIV-1 pathogenesis. The results of this study suggest that the virus continues to evolve against the selective pressure from some unmeasured host response during a partial treatment interruption of an envelope-specific drug. The results, however, are gained from a limited number of subjects. Further study of a large number of subjects with longer follow-up is needed.
